Biotalk Episode 13: 2023 Year-In-Review Report: Global Trends in Biopharma Transactions
In this episode, Geoff provides valuable insights into our report, focusing on critical areas such as: We invite you to […]
In this episode, Geoff provides valuable insights into our report, focusing on critical areas such as: We invite you to […]
2023 Year-In-Review Report: Global Trends in Biopharma Transactions Each quarter, Locust Walk’s deal team compiles key statistics and trends on
Podcast: Play in new window | Download (Duration: 32:27 — 74.3MB)
Subscribe: Apple Podcasts | Spotify | RSS
On this episode of Biotalk, Locust Walk‘s Geoff Meyerson welcomes Soufiane Aboulhouda, Co-Founder and Chairman of the Board of Nucleate, a global non-profit dedicated to
On this episode of Biotalk, Locust Walk‘s Daniel Brog welcomes with Shehnaaz Suliman, M.D., CEO of ReCode Therapeutics, a clinical-stage genetic medicines company using its
On this episode of Biotalk, Locust Walk‘s Geoff Meyerson welcomes Errik Anderson, CEO and Founder of Alloy Therapeutics, to the podcast. Alloy is a trailblazing
During this episode of Biotalk, Geoff Meyerson, CEO of Locust Walk, delves into our 2023 Q3 Report: Global Trends in Biopharma Transactions Report.
2023 Q3 Report: Global Trends in Biopharma Transactions Each quarter, Locust Walk’s deal team compiles key statistics and trends on
On this episode of Biotalk, Locust Walk‘s Andy Meyerson welcomes Helen Ho, Chief Business Officer of Blueprint Medicines, to the podcast. Blueprint Medicines is a
On this episode of Biotalk, Locust Walk‘s Geoff Meyerson welcomes Howard Federoff, MD PhD, Scientific Co-Founder, Chief Medical Officer, and Director of Ryne Biotechnology, to the